Vanguard Group’s Solid Biosciences SLDB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $19.5M | Buy |
3,454,959
+371,109
| +12% | +$2.01M | ﹤0.01% | 2629 |
|
|
2025
Q3 | $19M | Sell |
3,083,850
-281,697
| -8% | -$1.65M | ﹤0.01% | 2649 |
|
|
2025
Q2 | $16.4M | Buy |
3,365,547
+905,097
| +37% | +$3.2M | ﹤0.01% | 2646 |
|
|
2025
Q1 | $9.1M | Buy |
2,460,450
+1,059,192
| +76% | +$4.53M | ﹤0.01% | 2899 |
|
|
2024
Q4 | $5.61M | Buy |
1,401,258
+30,207
| +2% | +$166K | ﹤0.01% | 3229 |
|
|
2024
Q3 | $9.56M | Buy |
1,371,051
+12,668
| +0.9% | +$103K | ﹤0.01% | 2975 |
|
|
2024
Q2 | $7.7M | Buy |
1,358,383
+113,808
| +9% | +$1.02M | ﹤0.01% | 3057 |
|
|
2024
Q1 | $16.6M | Buy |
1,244,575
+920,404
| +284% | +$8.61M | ﹤0.01% | 2692 |
|
|
2023
Q4 | $1.99M | Buy |
324,171
+74,111
| +30% | +$237K | ﹤0.01% | 3607 |
|
|
2023
Q3 | $630K | Buy |
250,060
+2,018
| +0.8% | +$7.83K | ﹤0.01% | 3988 |
|
|
2023
Q2 | $1.3M | Buy |
248,042
+25,345
| +11% | +$143K | ﹤0.01% | 3819 |
|
|
2023
Q1 | $1.06M | Hold |
222,697
| – | – | ﹤0.01% | 3896 |
|
|
2022
Q4 | $1.2M | Buy |
222,697
+87
| +0% | +$570 | ﹤0.01% | 3851 |
|
|
2022
Q3 | $1.56M | Buy |
222,610
+49,874
| +29% | +$503K | ﹤0.01% | 3849 |
|
|
2022
Q2 | $1.59M | Buy |
172,736
+31,723
| +22% | +$330K | ﹤0.01% | 3903 |
|
|
2022
Q1 | $2.54M | Sell |
141,013
-30,877
| -18% | -$545K | ﹤0.01% | 3865 |
|
|
2021
Q4 | $4.51M | Sell |
171,890
-14,016
| -8% | -$428K | ﹤0.01% | 3665 |
|
|
2021
Q3 | $6.67M | Buy |
185,906
+1,721
| +0.9% | +$73.1K | ﹤0.01% | 3482 |
|
|
2021
Q2 | $10.1M | Sell |
184,185
-4,870
| -3% | -$322K | ﹤0.01% | 3189 |
|
|
2021
Q1 | $15.7M | Buy |
189,055
+76,997
| +69% | +$8.52M | ﹤0.01% | 2919 |
|
|
2020
Q4 | $12.7M | Buy |
112,058
+59,478
| +113% | +$3.76M | ﹤0.01% | 2865 |
|
|
2020
Q3 | $1.6M | Sell |
52,580
-3,262
| -6% | -$125K | ﹤0.01% | 3548 |
|
|
2020
Q2 | $2.46M | Sell |
55,842
-1,813
| -3% | -$75.3K | ﹤0.01% | 3374 |
|
|
2020
Q1 | $2.07M | Buy |
57,655
+168
| +0.3% | +$8.31K | ﹤0.01% | 3305 |
|
|
2019
Q4 | $3.84M | Buy |
57,487
+680
| +1% | +$75K | ﹤0.01% | 3257 |
|
|
2019
Q3 | $8.81M | Buy |
56,807
+1,452
| +3% | +$164K | ﹤0.01% | 2884 |
|
|
2019
Q2 | $4.77M | Buy |
55,355
+5,801
| +12% | +$633K | ﹤0.01% | 3185 |
|
|
2019
Q1 | $6.84M | Buy |
49,554
+16,092
| +48% | +$4.03M | ﹤0.01% | 3011 |
|
|
2018
Q4 | $13.5M | Sell |
33,462
-11,550
| -26% | -$5.43M | ﹤0.01% | 2624 |
|
|
2018
Q3 | $31.9M | Buy |
45,012
+20,286
| +82% | +$12.7M | ﹤0.01% | 2356 |
|
|
2018
Q2 | $13.2M | Buy |
24,726
+689
| +3% | +$212K | ﹤0.01% | 2762 |
|
|
2018
Q1 | $2.71M | Buy |
+24,037
| New | +$8.12M | ﹤0.01% | 3354 |
|
Other funds holding SLDB
PA
BCLSI
SL
VPC
RCM
AC
Vanguard Group's SLDB Position: Q4 2025 in Review
Vanguard Group increased its Solid Biosciences (SLDB) stake by 12% in Q4 2025, buying an estimated $2.01M and bringing the position to 3,454,959 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2629.
Vanguard Group first reported a position in SLDB in Q1 2018 and has held it in 32 quarters since. The position peaked at $31.9M in Q3 2018. 130 funds tracked by Wall St. Rank hold SLDB as of Q4 2025.
- Vanguard Group held 3,454,959 shares of Solid Biosciences worth $19.5M as of Q4 2025.
- Vanguard Group bought 371,109 Solid Biosciences shares in Q4 2025, an estimated $2.01M.
- Solid Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2629 holding.
- Vanguard Group first reported a position in Solid Biosciences in Q1 2018 and has held it in 32 quarters since.
- Vanguard Group's Solid Biosciences position peaked at $31.9M in Q3 2018.
- 130 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.